Author details

Full Name

Mariaemma Rodegher

Affiliation

ORCID

Career Start Year

1991

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
35105685	Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression.	Neurology: Neuroimmunology and NeuroInflammation	2022
33183125	Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis.	Multiple Sclerosis Journal	2021
33483938	Effects of Fingolimod and Natalizumab on Brain T1-/T2-Weighted and Magnetization Transfer Ratios: a 2-Year Study.		2021
33033898	Two-year macular volume assessment in multiple sclerosis patients treated with fingolimod.	Neurol Sci	2021
31452082	Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis.		2020
32111638	Two-year regional grey and white matter volume changes with natalizumab and fingolimod.	Journal of Neurology, Neurosurgery and Psychiatry	2020
32284874	The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis.	Multiple Sclerosis Journal - Experimental, Translational and Clinical	2020
30625050	Structural connectivity in multiple sclerosis and modeling of disconnection.	Multiple Sclerosis Journal	2020
31043476	Better explanations in multiple sclerosis diagnostic workup: A 3-year longitudinal study.	Neurology	2019
29173009	Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis.	Multiple Sclerosis Journal	2019
29683371	Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis.	Multiple Sclerosis Journal	2019
28273776	Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.	Multiple Sclerosis Journal	2018
28657428	Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis.	Multiple Sclerosis Journal	2018
30033621	Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response.	Acta Neurologica Scandinavica	2018
28294693	Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment.	Multiple Sclerosis Journal	2018
27714550	Mapping face encoding using functional MRI in multiple sclerosis across disease phenotypes.	Brain Imaging and Behavior	2017
28393349	Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes.	Acta Neurol Scand	2017
28349074	Dysregulation of MS risk genes and pathways at distinct stages of disease.	Neurol Neuroimmunol Neuroinflamm	2017
28905216	Slowly progressing varicella zoster brainstem encephalitis complicating Ramsay Hunt syndrome in an immunocompetent patient: case report and review of the literature.	Journal of NeuroVirology	2017
28881433	Structural connectivity-defined thalamic subregions have different functional connectivity abnormalities in multiple sclerosis patients: Implications for clinical correlations.	Human Brain Mapping	2017
27354020	Working memory network dysfunction in relapse-onset multiple sclerosis phenotypes: A clinical-imaging evaluation.	Multiple Sclerosis Journal	2017
27760859	Cerebellar contribution to motor and cognitive performance in multiple sclerosis: An MRI sub-regional volumetric analysis.	Multiple Sclerosis Journal	2017
26199350	Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients.	Multiple Sclerosis Journal	2016
27230789	Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.	Multiple Sclerosis Journal	2016
26474875	Efficacy and safety of nabiximols (Sativex(Â®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.	Neurol Sci	2016
26493126	Abnormal adaptation over time of motor network recruitment in multiple sclerosis patients with fatigue.	Multiple Sclerosis Journal	2016
24189776	Deficits in memory and visuospatial learning correlate with regional hippocampal atrophy in MS.	Brain Structure and Function	2015
25846708	Validation of 1-year predictive score of long-term response to interferon-Î² in everyday clinical practice multiple sclerosis patients.	European Journal of Neurology	2015
25583839	Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis.	Multiple Sclerosis Journal	2015
25914168	A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity.	Ann Neurol	2015
26788369	The Communication of Multiple Sclerosis Diagnosis: The Patients' Perspective.	Multiple Sclerosis International	2015
26362907	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.	Brain	2015
26185776	Impact of MS genetic loci on familial aggregation, clinical phenotype, and disease prediction.	Neurol Neuroimmunol Neuroinflamm	2015
26587553	Myeloid cells as target of fingolimod action in multiple sclerosis.	Neurology: Neuroimmunology and NeuroInflammation	2015
26287572	In vivo evidence of hippocampal dentate gyrus expansion in multiple sclerosis.	Human Brain Mapping	2015
26616872	Clinical significance of the number of oligoclonal bands in patients with clinically isolated syndromes.	Journal of Neuroimmunology	2015
25092808	Overcoming recruitment challenges in patients with multiple sclerosis: Results from an Italian survey.	Clinical Trials	2014
25877065	Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients.	Multiple Sclerosis and Related Disorders	2014
23812284	Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis.	Multiple Sclerosis Journal	2014
24591532	Optical coherence tomography and visual evoked potentials: which is more sensitive in multiple sclerosis?	Mult Scler	2014
24515732	Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study.	Mult Scler	2014
24927473	Regional but not global brain damage contributes to fatigue in multiple sclerosis.	Radiology	2014
24879733	Treatment of myelitis in BehÃ§et's disease with rituximab.	BMJ Case Reports	2014
23380649	Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis.	Multiple Sclerosis Journal	2013
22407022	A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy.	Neurological Sciences	2013
24076602	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.	Nat Genet	2013
23234810	Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome.	Mult Scler	2013
23354606	Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases.	Neurological Sciences	2013
23425504	Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.	European Journal of Neurology	2013
22108567	MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers.	Neuroscience Letters	2012